Roivant Sciences Ltd. Common Shares ROIV
$41.81
+0.80%
at last close
Market Cap$30.20 billion
P/E Ratio—
Div Yield—
Volume11.15M
52-Week Range
$10.90$42.50
Analyst Ratings
- Consensus
- Buy — 9 Buy · 1 Hold · 0 Sell (10 analysts)
- Avg. Price Target
- $38.75 (-7.3% downside)
Key Stats
- Today's Range
- $41.08 – $42.27
- 50-Day Range
- $32.47 – $42.50
- 52-Week Range
- $10.90 – $42.50
- Volume
- 11.15 million shs
- Average Volume
- 7.84 million shs
- Market Cap
- $30.20 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.11%
- Days to Cover
- 1.65
About Roivant Sciences Ltd. Common Shares
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Related Stocks
Compare head-to-head: ROIV vs LLY·ROIV vs JNJ·ROIV vs ABBV·ROIV vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.